DNTH stock soars 300% YTD on biotech breakthroughs. Latest DNTH stock price, analyst targets to $81, earnings preview. Is DNTH stock a buy?
Introduction
Dianthus Therapeutics develops treatments for autoimmune diseases. Its lead drug DNTH103 targets myasthenia gravis and other disorders using precision antibodies.
Investors watch DNTH stock after Phase 2 trial success doubled shares in weeks. Biopharma M&A heats up.
Biotech faces funding squeeze, but autoimmune space draws big pharma cash amid aging populations.
Latest stock Price & Trend
Last market close March 4, 2026 showed DNTH stock at $62.36. Volume spiked to 874K shares.
Daily gain 4.13% from $57.98 open, high $64.30. Five-day surge 25% on trial data.
One-month up 85%, three-month 140%, six-month 320%, YTD 186% from $21.80 start.
52-week high $64.30 today, low $13.37. Explosive bullish trend breaks all records.
Momentum attracts speculators, but biotech volatility demands tight risk controls.
Technical Analysis
Support at $57.98 intraday low, then $50 psychological. Resistance cleared at $64; next $75 gap.
RSI 78 screams overbought—above 70 warns of pullbacks as traders take profits.
MACD extremely bullish but diverging from price, potential stall signal.
50-day average $42 blasts past 200-day $28 in textbook golden cross.
Volume 40% above average confirms conviction buying. Parabolic move risks sharp reversal.
Analyst Ratings & Price Targets
11 analysts rate Strong Buy. Average target $65.22, high $92, low $34. Jefferies raised to $81.
Recent upgrades post-PPhase 2 data from Wedbush, Piper Sandler.
Wall Street sees 95% upside on pipeline potential. Biotech analysts rarely this unified.
Insider Activity
CEO bought 15K shares at $55 post-trial ($825K). Directors added positions steadily.
No sales reported; lockup insiders accumulating. Management skin in game grows.
Heavy buying screams confidence in commercial path ahead.
Valuation Analysis
No P/E—unprofitable biotech. Price-to-sales 218x on $4.85M revenue TTM. Cash $450M funds ops.
Net loss $114M; EPS -$3.25. Market cap $2.7B reflects pipeline dreams.
Peers like Harmony Biosciences trade 5x sales profitably—DNTH premium justified by data? Early stage valued on potential, not profits.
Recent Earnings & Catalysts
Q3 2025 EPS beat estimates (-$0.82 vs -$0.85 expected). Cash burn controlled.
Next earnings Nov 6, 2025. Phase 2 DNTH103 data crushed endpoints—95% response rate.
Catalysts: Phase 3 start H1 2026, partnership rumors with AstraZeneca. Shares tripled on trial news.
Bullish Case
DNTH103 could dominate $3B myasthenis market. Best-in-class potency profile.
$450M cash runway to 2028. Orphan drug status accelerates FDA path.
M&A bait—big pharma pays 5-10x for late-stage autoimmunes.
Bearish Case
Phase 3 failure tanks 70%+ typical. Competition from J&J, argenx.
Dilution risk with $150M annual burn. Regulatory delays common.
Macro credit crunch hits biotech funding hard.
Market Sentiment & Investor Psychology
Short interest unknown but likely low given squeeze potential. Calls exploding.
Institutions scrambling in (45% ownership up sharply). Retail biotech traders pile on.
Sentiment euphoric—classic blow-off top setup or breakout?
Short-Term Outlook
Overbought RSI plus MACD divergence screams consolidation. Profit-taking hits $55-58 support.
Trial momentum fades without news. Choppy range trading likely.
Medium to Long-Term Outlook
Pipeline delivers or dies. $3B peak sales potential if approved.
Financials solid to Phase 3 readout. Accumulate dips under $50 for conviction holders.
FAQ
Is DNTH stock a buy right now?
Speculative buy on pullbacks; avoid chasing highs.
What is the price target for DNTH stock?
$65.22 average, $81 Jefferies high. 5% upside.
What are major risks for DNTH stock?
Clinical failure, dilution, competition, M&A flop.
DNTH earnings date?
November 6, 2025 expected.
DNTH stock forecast 2026?
$75+ if Phase 3 advances smoothly.
Suggestions
Compare with Opendoor analysis.
See our myasthenia gravis treatment pipeline.
Read biotech M&A valuation trends 2026.
Conclusion
Watchlist DNTH stock. Trial fireworks create opportunity but frothy valuations demand patience. Key support $58.
Disclaimer: This article is for informational purposes only and not financial advice.